$4,750.00
In 2020, the global market for implantable pacemaker products totaled nearly $3.9bn, with dual-chamber products accounting for nearly 75% of sales. Over the forecast period covered by this report, single-chamber pacemaker devices are expected to experience greater growth than the dual-chamber market, advancing at a CAGR of approximately 6.8%. Drivers include a growing prevalence of cardiovascular disease due to the aging population, the development of leadless pacemaker systems, and expanded indications. Additionally, there is strong evidence of a correlation between COVID-19 and the development of atrial arrythmias.
In 2020, the global market for implantable pacemaker products totaled nearly $3.9bn, with dual-chamber products accounting for nearly 75% of sales. Over the forecast period covered by this report, single-chamber pacemaker devices are expected to experience greater growth than the dual-chamber market, advancing at a CAGR of approximately 6.8%. Drivers include a growing prevalence of cardiovascular disease due to the aging population, the development of leadless pacemaker systems, and expanded indications. Additionally, there is strong evidence of a correlation between COVID-19 and the development of atrial arrythmias. Given the scale of the pandemic, combined with this trend, there is the strong possibility of a short-term increase in patients requiring pacemakers. Limiters include device cost, lack of long-term data for leadless technology, and lack of trained operators and facilities in certain geographic regions. Another major short-term concern is that rising geopolitical tensions combined with the effects of the COVID-19 pandemic have resulted in a series of bottlenecks hampering the production and distribution of the chips used in pacemakers and other medical devices. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for pacemaker systems for the US, five major European markets, Japan, and Rest of World markets for the years 2019–25.
Executive Summary ………………………………………………………………………. ES-1
i. Cardiac rhythm disorders overview………………………………………………………………………..ES-1
ii. Global implantable pacemaker products market …………………………………………………….ES-1
a. Market drivers and limiters……………………………………………………………………….ES-3
b. Device segment insights …………………………………………………………………………..ES-4
c. Technology trends……………………………………………………………………………………ES-4
d. Market leaders………………………………………………………………………………………..ES-5
e. Competitive strategies……………………………………………………………………………..ES-5
f. Emerging competition ………………………………………………………………………………ES-5
iii. Methodology……………………………………………………………………………………………………..ES-6
Exhibit ES-1: Global implantable pacemaker products, market forecast ($m), 2019–25…..ES-2
Exhibit ES-2: Global implantable pacemaker products market, by country/region, 2020 …ES-3
Exhibit ES-3: Drivers and limiters of growth – implantable pacemaker products…………….ES-4
1. Cardiac Rhythm Disorders Overview ……………………………………………….1-1
1.1 Sick sinus syndrome…………………………………………………………………………………………… 1-4
1.2 Bradycardia ………………………………………………………………………………………………………. 1-4
1.3 Heart block……………………………………………………………………………………………………….. 1-5
1.4 Tachycardia ………………………………………………………………………………………………………. 1-6
1.5 Atrial fibrillation ………………………………………………………………………………………………… 1-7
1.6 Heart failure ……………………………………………………………………………………………………… 1-9
1.7 Diagnosis and treatment……………………………………………………………………………………….11
1.8 Impact of COVID-19 …………………………………………………………………………………………. 1-11
1.9 Bibliography ……………………………………………………………………………………………………. 1-13
Exhibit 1-1: Estimated prevalence rates of conduction disorders and cardiac arrhythmias, based on healthcare utilization, select countries…………………………………………….. 1-2
Exhibit 1-2: Estimated number of hospital discharges for conduction disorders and cardiac arrhythmias, select countries ……………………………………………………………………….. 1-3
Exhibit 1-3: Estimated prevalence of atrial fibrillation, select countries, 2021………………… 1-8
Exhibit 1-4: Estimated prevalence of chronic heart failure, select countries, 2021………….. 1-9
Exhibit 1-5: Estimated prevalence of acute decompensated heart failure, select countries, 2021………………………………………………………………………………… 1-10
2. Pacemaker Devices ………………………………………………………………………2-1
2.1 Implantable pacemaker systems…………………………………………………………………………. 2-2
2.1.1 Implantable pacemaker products………………………………………………………….. 2-3
2.1.2 Developments in implantable pacemaker technology ……………………………… 2-5
2.2 Temporary pacing systems …………………………………………………………………………………. 2-9
2.2.1 External pacemaker products……………………………………………………………… 2-10
2.3 Bibliography ……………………………………………………………………………………………………. 2-11
Exhibit 2-1: NBG code for implantable pacemaker systems………………………………………….. 2-3
Exhibit 2-2: Selected implantable pacemakers and manufacturers……………………………….. 2-4
Exhibit 2-3: EBR Systems’ WiSE CRT system ……………………………………………………………….. 2-8
Exhibit 2-4: Combination of Micra and WiSE CRT systems……………………………………………. 2-9
Exhibit 2-5: Selected external pacemakers and manufacturers…………………………………… 2-10
3. Implantable Pacemaker Market……………………………………………………..3-1
3.1 Global market insights……………………………………………………………………………………….. 3-1
3.1.1 Market value………………………………………………………………………………………. 3-2
3.1.2 Technology trends ………………………………………………………………………………. 3-6
3.1.3 Market drivers and limiters ………………………………………………………………….. 3-7
3.1.4 Implantable pacemaker products overview ……………………………………………. 3-8
3.1.5 Market leaders………………………………………………………………………………….. 3-10
3.1.6 Competitive strategies……………………………………………………………………….. 3-10
3.1.7 Emerging competition ……………………………………………………………………….. 3-11
3.2 Global competitors ………………………………………………………………………………………….. 3-12
3.3 Market forecast……………………………………………………………………………………………….. 3-16
3.3.1 Market forecast: US …………………………………………………………………………… 3-16
3.3.2 Market forecast: five major European markets……………………………………… 3-20
3.3.3 Market forecast: Japan ………………………………………………………………………. 3-24
3.3.4 Market forecast: rest of world…………………………………………………………….. 3-27
3.4 Bibliography ……………………………………………………………………………………………………. 3-32
Exhibit 3-1: Global implantable pacemaker products market, by product type ($m), 2019–25 …………………………………………………………………….. 3-3
Exhibit 3-2: Global implantable pacemaker products market, by country/region, 2020 ………………………………………………………………………………. 3-5
Exhibit 3-3: Global implantable pacemaker products market, by country/region ($m), 2019–25…………………………………………………………………. 3-6
Exhibit 3-4: Drivers and limiters of market growth – implantable pacemaker products…… 3-8
Exhibit 3-5: Global implantable pacemaker products market, by product type, 2019 and 2025………………………………………………………………….. 3-10
Exhibit 3-6: Medtronic, revenues by segment ($m), FY2021 ………………………………………. 3-13
Exhibit 3-7: Abbott, revenues by segment, FY2020……………………………………………………. 3-14
Exhibit 3-8: Boston Scientific, revenues by segment, FY2020 ……………………………………… 3-15
Exhibit 3-9: Global implantable pacemaker products market, by supplier, 2020 …………… 3-16
Exhibit 3-10: US implantable pacemaker products market, procedure volumes forecast (000s), 2019–25……………………………………………….. 3-18
Exhibit 3-11: US implantable pacemaker products market, by product type ($m), 2019–25 …………………………………………………………………… 3-19
Exhibit 3-12: US implantable pacemaker products market, by supplier, 2020 ………………. 3-20
Exhibit 3-13: 5 Euro implantable pacemaker products market, procedure volumes forecast (000s), 2019–25……………………………………………….. 3-22
Exhibit 3-14: 5 Euro implantable pacemaker products market, by product type ($m), 2019–25 …………………………………………………………………… 3-23
Exhibit 3-15: 5 Euro implantable pacemaker products market, by supplier, 2020……………………………………………………………………………………….. 3-24
Exhibit 3-16: Japan implantable pacemaker products market, procedure volumes forecast (000s), 2019–25 ………………………………………………………………………………………… 3-25
Exhibit 3-17: Japan implantable pacemaker products market, by product type ($m), 2019–25 ………………………………………………………………….. 3-26
Exhibit 3-18: Japan implantable pacemaker products market, by supplier, 2020 ………….. 3-27
Exhibit 3-19: RoW implantable pacemaker products market, by product type ($m), 2019–25 …………………………………………………………………… 3-30
Exhibit 3-20: RoW implantable pacemaker products market, by supplier, 2020……………. 3-31
Appendix: Company Listing……………………………………………………………… A-1
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!